Successful Early Rescue with Isatuximab Plus Carfilzomib-Dexamethasone (ISA-KD) in Daratumumab-Refractory Newly Diagnosed Multiple Myeloma (NDMM) Patients with “No Washout Period”: A Real-World Clinical Experience in A Case Series and Literature Review

Authors

  • Paula Gili Herreros
  • Patricia García Ramírez
  • Xabier Gutiérrez López de Ocáriz
  • Marta Callejas Charavía
  • Julio García-Suárez
  • Juan José Gil-Fernández

Abstract

Introduction: Anti-CD38 monoclonal antibodies, such as daratumumab and isatuximab, are key agents in multiple myeloma treatment. However, sequential use without a washout period remains controversial due to resistance concerns.
Methods: We conducted a retrospective, real-world study of five newly diagnosed multiple myeloma (NDMM) patient’s refractory to daratumumab-based induction. Between June 2022 and December 2024, patients from two Spanish centers received isatuximab-carfilzomibdexamethasone (ISA-KD) immediately after daratumumab failure.
Results: All patients achieved rapid, deep responses, enabling autologous stem cell transplantation in two cases.
Conclusion: These findings suggest that immediate anti-CD38 switching

Downloads

Published

2026-01-09

How to Cite

Herreros, P. G., Ramírez, P. G., Ocáriz, X. G. L. de, Charavía, M. C., García-Suárez, J., & Gil-Fernández, J. J. (2026). Successful Early Rescue with Isatuximab Plus Carfilzomib-Dexamethasone (ISA-KD) in Daratumumab-Refractory Newly Diagnosed Multiple Myeloma (NDMM) Patients with “No Washout Period”: A Real-World Clinical Experience in A Case Series and Literature Review. Archives of Clinical and Medical Case Reports, 10(1), 1–5. Retrieved from https://fortunejournals.org/ojs/index.php/acmcr/article/view/23020

Issue

Vol. 10 No. 1 (2026): Volume 10, Issue 1

Section

Articles